To aid our viewers to follow the topics discussed please see the following guidance:
||Limitations of FFR & Discussion
||Perera / Van Belle / Sharp / Achenbach
||Introduction to iFR, where does it fit into the physiology sphere and summary of data
||iFR vs Pd/Pa
||Achenbach / Gotberg / Baptista
||Why iFR is an option and ongoing trial summary
||Sharp / Van Belle / Gotberg
||Coronary Flow Velocity
Simon Kennon, Interventional Cardiologist and Head of the Transcatheter Aortic Valve Implantation Programme, London Chest Hospital, London, UK
Stephan Achenbach, Professor of Cardiology, University of Erlangen-Nürnberg, Erlangen, Germany
Sergio Bravo Baptista, Cardiology Department, Hospital Fernando Fonseca, Amadora, Portugal
Matthias Gotberg, Director of Cardiac Cath Laboratory, Lund University, Lund, Sweden
Divaka Perera, Consultant Cardiologist, Guy's & St Thomas' Hospital, London, UK
Andrew Sharp, Consultant Cardiologist, Royal Devon and Exeter Hospital, Exeter, UK
Eric Van Belle, Professor-Head of Interventional Cardiology, University of Lille Hospital, France
Simon Kennon has no disclosures
Stephan Achenbach receives research contracts (institutional) from Siemens Healthcare & Abbott Vascular.
Sergio Baptista has received an investigation grant and also consultant fees from St. Jude Medical.
Mathias Gotberg proctors and receives minor consulting fees for Boston Scientific, minor consulting for Medtronic and minor consulting for Volcano. He is also PI for the iFR-Swedeheart trial which is supported by Volcano through an unrestricted research grant.
Divaka Perera has received research funding and speaker's fees from Maquet
Andrew Sharp has received speakers honoraria from Volcano
Eric Van Belle disclosed being a consultant from St Jude Medical and receiving speaker's fees from Volcano
The assigned learning objectives for this roundtable are listed for your information:
- To review the real-world utilisation and performance of coronary physiology assessment
- To consider recent and emerging data on coronary physiology assessment technology in particular in non-culprit disease, and in the setting of a diagnostic catheterization
- To discuss on-going coronary physiology assessment research
- To identify and refine the indications for utilisation of coronary physiology assessment in particular in non-culprit ACS, and diagnostic catheterizations
- To establish the nature of future coronary physiology research and technology developments
This educational activity is intended for an international audience, specifically interventional cardiologists and cardiologists. However, other healthcare professionals involved in the care of coronary artery disease (CAD) patients will also find this topical.
This roundtable discussion was sponsored by Volcano Corporation